BO-112
Basal Cell Carcinoma (BCC)
Key Facts
About Highlight Therapeutics
Highlight Therapeutics is a clinical-stage biotech pioneering intra-lesional RNA therapies to activate the immune system against cancer, with a primary focus on skin cancers. The company's lead asset, BO-112, is in Phase 2b development for basal cell carcinoma (BCC) and has shown promise in combination with anti-PD-1 agents. Leveraging a unique approach to convert immunologically 'cold' tumors 'hot,' Highlight aims to address significant unmet needs in dermato-oncology, a field with a large and growing patient population. The company operates as a private, pre-revenue entity advancing its pipeline through clinical trials.
View full company profileAbout Highlight Therapeutics
Highlight Therapeutics is a clinical-stage biotech pioneering intra-lesional RNA therapies to activate the immune system against cancer, with a primary focus on skin cancers. The company's lead asset, BO-112, is in Phase 2b development for basal cell carcinoma (BCC) and has shown promise in combination with anti-PD-1 agents. Leveraging a unique approach to convert immunologically 'cold' tumors 'hot,' Highlight aims to address significant unmet needs in dermato-oncology, a field with a large and growing patient population. The company operates as a private, pre-revenue entity advancing its pipeline through clinical trials.
View full company profileTherapeutic Areas
Other Basal Cell Carcinoma (BCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Skinject Patch | Skinject | Pre-clinical |
| SKNJCT-001 | Medicus Pharma | Phase II |